JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$761M |
| 2 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$735M |
| 3 |
Zimmer Biomet
ZBH
|
+$542M |
| 4 |
Amazon
AMZN
|
+$439M |
| 5 |
iShares Core MSCI EAFE ETF
IEFA
|
+$438M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.01B |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$1.11B |
| 3 |
AABA
Altaba Inc
AABA
|
+$699M |
| 4 |
TJX Companies
TJX
|
+$682M |
| 5 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 22.01% |
| 2 | Financials | 14.82% |
| 3 | Technology | 12.49% |
| 4 | Healthcare | 9.61% |
| 5 | Consumer Discretionary | 8.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2526
PUT
Intuitive Surgical
ISRG
$140B
| $5.25M | ﹤0.01% |
43,200
| – | – |
2017 Q2
2 quarters
|
|
2527
Globalstar
GSAT
$10.8B
| $5.25M | ﹤0.01% |
+267,071
| New | +$6.08M |
2017 Q4
0 quarters
|
|
|
CS
2528
DELISTED
Credit Suisse Group
CS
| $5.24M | ﹤0.01% |
293,654
-21,645
| -7% | -$358K |
2013 Q2
18 quarters
|
|
|
SCS
2529
DELISTED
Steelcase
SCS
| $5.23M | ﹤0.01% |
344,214
+88,792
| +35% | +$1.3M |
2013 Q2
18 quarters
|
|
|
CIVI
2530
DELISTED
Civitas Solutions, Inc.
CIVI
| $5.22M | ﹤0.01% |
305,392
-6,608
| -2% | -$123K |
2015 Q4
8 quarters
|
|
2531
First Trust North American Energy Infrastructure Fund
EMLP
$3.96B
| $5.22M | ﹤0.01% |
212,571
-17,420
| -8% | -$429K |
2013 Q2
18 quarters
|
|
2532
Par Pacific Holdings
PARR
$4.23B
| $5.21M | ﹤0.01% |
270,302
+193,673
| +253% | +$3.93M |
2017 Q2
2 quarters
|
|
|
ZGNX
2533
DELISTED
Zogenix, Inc.
ZGNX
| $5.21M | ﹤0.01% |
130,020
-121,580
| -48% | -$4.67M |
2015 Q4
8 quarters
|
|
|
AAV
2534
DELISTED
Advantage Oil & Gas Ltd
AAV
| $5.19M | ﹤0.01% |
1,207,770
+127,728
| +12% | +$643K |
2016 Q2
6 quarters
|
|
2535
First Trust Dorsey Wright International Focus 5 ETF
IFV
$217M
| $5.19M | ﹤0.01% |
233,055
+27,348
| +13% | +$596K |
2017 Q1
3 quarters
|
|
2536
Heron Therapeutics
HRTX
$71.9M
| $5.16M | ﹤0.01% |
285,208
+283,000
| +12,817% | +$4.61M |
2015 Q3
9 quarters
|
|
|
RTEC
2537
DELISTED
Rudolph Technologies Inc
RTEC
| $5.15M | ﹤0.01% |
215,510
-4,472
| -2% | -$115K |
2015 Q3
9 quarters
|
|
2538
CALL
GSK
GSK
$94.2B
| $5.14M | ﹤0.01% |
116,000
| – | – |
2017 Q3
1 quarter
|
|
2539
CytomX Therapeutics
CTMX
$567M
| $5.14M | ﹤0.01% |
243,539
+4,989
| +2% | +$103K |
2016 Q4
4 quarters
|
|
2540
Mueller Industries
MLI
$13.9B
| $5.13M | ﹤0.01% |
579,656
+145,040
| +33% | +$1.27M |
2013 Q2
18 quarters
|
|
|
GTS
2541
DELISTED
Triple-S Management Corporation
GTS
| $5.13M | ﹤0.01% |
216,914
+29,986
| +16% | +$731K |
2015 Q4
8 quarters
|
|
2542
PUT
The Kraft Heinz Company
KHC
$26.3B
| $5.12M | ﹤0.01% |
65,800
-149,600
| -69% | -$11.8M |
2015 Q4
8 quarters
|
|
|
CPLA
2543
DELISTED
Capella Education Company
CPLA
| $5.11M | ﹤0.01% |
66,074
+13,378
| +25% | +$1.04M |
2013 Q2
18 quarters
|
|
2544
Arcos Dorados Holdings
ARCO
$1.48B
| $5.11M | ﹤0.01% |
507,370
-361,118
| -42% | -$3.53M |
2015 Q4
8 quarters
|
|
|
FLOW
2545
DELISTED
SPX FLOW, Inc.
FLOW
| $5.1M | ﹤0.01% |
107,288
+79,603
| +288% | +$3.43M |
2015 Q3
9 quarters
|
|
2546
PUT
Newell Brands
NWL
$2.29B
| $5.1M | ﹤0.01% |
165,000
-11,200
| -6% | -$386K |
2017 Q3
1 quarter
|
|
|
OPTU
2547
PUT
Optimum Communications Inc
OPTU
$359M
| $5.09M | ﹤0.01% |
+240,000
| New | +$5.31M |
2017 Q4
0 quarters
|
|
|
FCE.A
2548
DELISTED
Forest City Realty Trust, Inc.
FCE.A
| $5.09M | ﹤0.01% |
211,241
+161,392
| +324% | +$4M |
2013 Q2
18 quarters
|
|
2549
WD-40
WDFC
$2.73B
| $5.08M | ﹤0.01% |
43,014
+39,181
| +1,022% | +$4.49M |
2013 Q2
18 quarters
|
|
|
MITT
2550
TPG Mortgage Investment Trust
MITT
$184M
| $5.07M | ﹤0.01% |
88,941
+1,713
| +2% | +$98.8K |
2015 Q4
8 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2017 Portfolio in Review
As of Q4 2017, JP Morgan Chase held 5,783 positions worth $475B, up 4.7% from $453B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q4 2017 filing shows 812 new, 2,513 increased, 1,655 reduced and 342 closed positions. Its largest new stake was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $4.01B.
By sector, the portfolio is most concentrated in Miscellaneous at 22% of assets, down from 24% a quarter earlier, followed by Financials and Technology.
- JP Morgan Chase's largest Q4 2017 buy was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M.
- JP Morgan Chase added most to Johnson & Johnson in Q4 2017, an estimated $761M increase.
- JP Morgan Chase's biggest Q4 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $4.01B.
- JP Morgan Chase fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $275M.
- JP Morgan Chase's ten largest holdings make up 18% of its $475B portfolio in Q4 2017.
- JP Morgan Chase opened 812 new positions and closed 342 in Q4 2017.
- JP Morgan Chase's portfolio value rose 4.7% quarter-over-quarter to $475B.
Based on JP Morgan Chase's 13F filing for Q4 2017, filed 13 Feb 2018.